Teva Pharmaceutical Industries Limited (NYSE:TEVA)‘s stock had its “market perform” rating reissued by equities research analysts at Cowen and Company in a research report issued to clients and investors on Wednesday. They presently have a $18.00 target price on the stock, down from their prior target price of $30.00. Cowen and Company’s target price points to a potential upside of 11.94% from the company’s previous close.

Other equities analysts also recently issued research reports about the company. Mizuho raised Teva Pharmaceutical Industries Limited from a “neutral” rating to a “buy” rating and increased their price target for the stock from $25.00 to $30.00 in a research report on Thursday, June 15th. Royal Bank Of Canada set a $38.00 price target on Teva Pharmaceutical Industries Limited and gave the stock a “buy” rating in a research report on Friday, June 16th. Oppenheimer Holdings, Inc. set a $41.00 price target on Teva Pharmaceutical Industries Limited and gave the stock a “buy” rating in a research report on Tuesday, June 27th. BidaskClub raised Teva Pharmaceutical Industries Limited from a “hold” rating to a “buy” rating in a research report on Wednesday, July 5th. Finally, Vetr raised Teva Pharmaceutical Industries Limited from a “hold” rating to a “buy” rating and set a $32.27 price target on the stock in a research report on Tuesday, July 11th. Four equities research analysts have rated the stock with a sell rating, nineteen have assigned a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. Teva Pharmaceutical Industries Limited has an average rating of “Hold” and a consensus price target of $30.39.

Shares of Teva Pharmaceutical Industries Limited (NYSE TEVA) traded down 14.56% during mid-day trading on Wednesday, hitting $16.08. 79,140,054 shares of the stock were exchanged. Teva Pharmaceutical Industries Limited has a 12 month low of $15.22 and a 12 month high of $45.95. The stock’s 50 day moving average is $17.05 and its 200 day moving average is $27.05. The firm’s market cap is $16.34 billion.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last posted its quarterly earnings results on Thursday, August 3rd. The company reported $0.99 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.06 by ($0.07). Teva Pharmaceutical Industries Limited had a positive return on equity of 15.96% and a negative net margin of 25.18%. The firm had revenue of $5.69 billion for the quarter, compared to the consensus estimate of $5.72 billion. During the same period in the previous year, the company posted $1.25 EPS. Teva Pharmaceutical Industries Limited’s quarterly revenue was up 12.9% compared to the same quarter last year. Analysts expect that Teva Pharmaceutical Industries Limited will post $4.31 EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This piece of content was originally posted by American Banking News and is the property of of American Banking News. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of US & international copyright & trademark law. The legal version of this piece of content can be read at https://www.americanbankingnews.com/2017/10/04/cowen-and-company-reaffirms-market-perform-rating-for-teva-pharmaceutical-industries-limited-teva.html.

Several institutional investors have recently bought and sold shares of the company. San Francisco Sentry Investment Group CA acquired a new stake in shares of Teva Pharmaceutical Industries Limited in the second quarter worth approximately $106,000. Kistler Tiffany Companies LLC boosted its stake in shares of Teva Pharmaceutical Industries Limited by 74.7% in the second quarter. Kistler Tiffany Companies LLC now owns 3,673 shares of the company’s stock worth $122,000 after acquiring an additional 1,571 shares during the last quarter. Bronfman E.L. Rothschild L.P. boosted its stake in shares of Teva Pharmaceutical Industries Limited by 2.6% in the second quarter. Bronfman E.L. Rothschild L.P. now owns 3,711 shares of the company’s stock worth $123,000 after acquiring an additional 94 shares during the last quarter. FNY Managed Accounts LLC acquired a new stake in shares of Teva Pharmaceutical Industries Limited in the first quarter worth approximately $123,000. Finally, Sterling Investment Advisors Ltd. boosted its stake in shares of Teva Pharmaceutical Industries Limited by 2.6% in the first quarter. Sterling Investment Advisors Ltd. now owns 3,900 shares of the company’s stock worth $125,000 after acquiring an additional 100 shares during the last quarter. Institutional investors and hedge funds own 56.77% of the company’s stock.

Teva Pharmaceutical Industries Limited Company Profile

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Analyst Recommendations for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with MarketBeat.com's FREE daily email newsletter.